Martina Henrichsmann1, Georg Hempel2. 1. Institute of Pharmaceutical and Medical Chemistry, Westfälische Wilhelms-University Münster, Corrensstraße 48, 48149, Münster, Germany. martina.henrichsmann@gmx.de. 2. Institute of Pharmaceutical and Medical Chemistry, Westfälische Wilhelms-University Münster, Corrensstraße 48, 48149, Münster, Germany.
Abstract
BACKGROUND: Since the new German Apothekenbetriebsordnung was released, medication therapy management (MTM) has increased in importance. MTM is intended to improve the quality of life of patients. OBJECTIVES: The aim of this study was to improve the quality of life of patients with Parkinson's disease through an MTM by a community pharmacist. SETTING: The patients were recruited in cooperation with the Deutsche Parkinson Vereinigung e.V. (dPV) in Germany. Methods All patients were evaluated at baseline (t0) and after a follow-up of 4 months (t1). During the intervention period, the pharmacists implemented an MTM with standardized pharmaceutical care. Main outcome measure The effects of the interventions were measured by the Unified Parkinson Disease Rating Scale (UPDRS) and the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). RESULTS: In this study, 90 patients with Parkinson's disease were included. The most common intervention was to find a therapy for untreated comorbidities. The UPDRS or MDS-UPDRS improved significantly after the intervention period by a median change rate of 1 (p < 0.05) or rather 2 (p < 0.05) compared to the baseline. CONCLUSION: The study shows that the quality of life in Parkinson's disease patients improved significantly through MTM.
BACKGROUND: Since the new German Apothekenbetriebsordnung was released, medication therapy management (MTM) has increased in importance. MTM is intended to improve the quality of life of patients. OBJECTIVES: The aim of this study was to improve the quality of life of patients with Parkinson's disease through an MTM by a community pharmacist. SETTING: The patients were recruited in cooperation with the Deutsche Parkinson Vereinigung e.V. (dPV) in Germany. Methods All patients were evaluated at baseline (t0) and after a follow-up of 4 months (t1). During the intervention period, the pharmacists implemented an MTM with standardized pharmaceutical care. Main outcome measure The effects of the interventions were measured by the Unified Parkinson Disease Rating Scale (UPDRS) and the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). RESULTS: In this study, 90 patients with Parkinson's disease were included. The most common intervention was to find a therapy for untreated comorbidities. The UPDRS or MDS-UPDRS improved significantly after the intervention period by a median change rate of 1 (p < 0.05) or rather 2 (p < 0.05) compared to the baseline. CONCLUSION: The study shows that the quality of life in Parkinson's diseasepatients improved significantly through MTM.
Entities:
Keywords:
Community pharmacist; Germany; Medication therapy management; Parkinson’s disease; Pharmaceutical care
Authors: G P Samsa; J T Hanlon; K E Schmader; M Weinberger; E C Clipp; K M Uttech; I K Lewis; P B Landsman; H J Cohen Journal: J Clin Epidemiol Date: 1994-08 Impact factor: 6.437
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Jori Fleisher; William Barbosa; Meghan M Sweeney; Sarah E Oyler; Amy C Lemen; Arash Fazl; Mia Ko; Talia Meisel; Naomi Friede; Geraldine Dacpano; Rebecca M Gilbert; Alessandro Di Rocco; Joshua Chodosh Journal: J Am Geriatr Soc Date: 2018-04-02 Impact factor: 5.562